Darzalex Faspro
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Darzalex Faspro
- Generic name
- DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)
- Manufacturer
- Janssen Biotech, Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 4bb241af-4299-4373-8762-2d6709515db0
- SPL ID
- 7f8d76d6-da40-408e-8dcc-e16df836db77
- Version
- 34
- Effective date
- 2026-10-12
- Source export date
- 2026-11-13
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:34:49
| Harmonized routes |
|---|
| SUBCUTANEOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 761145 | derived:openfda.application_number |
| application number | BLA761145 | openfda.application_number | |
| brand name | Darzalex Faspro | openfda.brand_name | |
| generic name | DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT) | openfda.generic_name | |
| manufacturer name | Janssen Biotech, Inc. | openfda.manufacturer_name | |
| ndc | package | 57894-503-01 | openfda.package_ndc |
| ndc | product | 57894-503 | openfda.product_ndc |
| ndc11 | package | 57894050301 | derived:openfda.package_ndc |
| rxcui | 2375136 | openfda.rxcui | |
| rxcui | 2375141 | openfda.rxcui | |
| spl id | 7f8d76d6-da40-408e-8dcc-e16df836db77 | id | |
| spl set id | 4bb241af-4299-4373-8762-2d6709515db0 | set_id | |
| unii | 4Z63YK6E0E | openfda.unii | |
| unii | 743QUY4VD8 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hypersensitivity and Other Administration Reactions : Permanently discontinue DARZALEX FASPRO for life-threatening reactions. ( 5.1 ) Cardiac Toxicity in Patients with Light Chain (AL) Amyloidosis : Monitor patients with cardiac involvement more frequently for cardiac adverse reactions and administer supportive care as appropriate. ( 5.2 ) Infections : DARZALEX FASPRO can cause serious and fatal infections. Monitor patients for signs and symptoms of infection and treat appropriately. ( 5.3 ) Neutropenia : Monitor complete blood cell counts periodically during treatment. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO to allow recovery of neutrophils. ( 5.4 ) Thrombocytopenia : Monitor complete blood cell counts periodically during treatment. Consider withholding DARZALEX FASPRO to allow recovery of platelets. ( 5.5 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise pregnant women of the potential risk to a fetus and advise females of reproductive potential to use effective contraception. ( 5.6 , 8.1 , 8.3 ) Interference with cross-matching and red blood cell antibody screening : Type and screen patients prior to starting treatment. Inform blood banks that a patient has received DARZALEX FASPRO. ( 5.7 , 7.1 ) 5.1 Hypersensitivity and Other Administration Reactions Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO. Fatal reactions have been reported with daratumumab-containing products, including DARZALEX FASPRO [see Adverse Reactions (6.2) ] . Systemic Reactions In a pooled safety population of 1446 patients with multiple myeloma (N=1253) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO as monotherapy or as part of a combination therapy, 7% of patients experienced a systemic administration-related reaction (Grade 2: 3%, Grade 3: 0.8%, Grade 4: 0.1%). In patients with high-risk smoldering multiple myeloma (N=193), systemic administration-related reactions occurred in 17% of patients in AQUILA (Grade 2: 7%, Grade 3: 1%). In all patients (N=1639), systemic administration-related reactions occurred in 7% of patients with the first injection, 0.5% with the second injection, and cumulatively 1% with subsequent injections. The median time to onset was 3.2 hours (range: 4 minutes to 3.5 days). Of the 283 systemic administration-related reactions that occurred in 135 patients, 240 (85%) occurred on the day of DARZALEX FASPRO administration. Delayed systemic administration-related reactions have occurred in 1% of the patients. Severe reactions include hypoxia, dyspnea, hypertension, and tachycardia, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, chills, vomiting, nausea, hypotension, and blurred vision. Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen and corticosteroids [see Dosage and Administration (2.6) ] . Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO. Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions [see Dosage and Administration (2.6) ] . Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with daratumumab-containing products. If ocular symptoms occur, interrupt DARZALEX FASPRO and seek immediate ophthalmologic evaluation prior to restarting DARZALEX FASPRO. Local Reactions In this pooled safety population of 1446 patients with multiple myeloma (N=1253) or light chain (AL) amyloidosis (N=193), injection-site reactions occurred in 8% of patients, including Grade 2 reactions in 1.1%. The most frequent (>1%) injection-site reactions were injection site erythema and injection site rash. In patients with high-risk smoldering multiple myeloma (N=193), injection-site reactions occurred in 28% of patients, including Grade 2 reactions in 3%. These local reactions occurred a median of 6 minutes (range: 0 minutes to 6.5 days) after starting administration of DARZALEX FASPRO. Monitor for local reactions and consider symptomatic management. 5.2 Cardiac Toxicity in Patients with Light Chain (AL) Amyloidosis Serious or fatal cardiac adverse reactions occurred in patients with light chain (AL) amyloidosis who received DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone [see Adverse Reactions (6.1) ] . Serious cardiac disorders occurred in 16% and fatal cardiac disorders occurred in 10% of patients. Patients with NYHA Class IIIA or Mayo Stage IIIA disease may be at greater risk. Patients with NYHA Class IIIB or IV disease were not studied. Monitor patients with cardiac involvement of light chain (AL) amyloidosis more frequently for cardiac adverse reactions and administer supportive care as appropriate. 5.3 Infections DARZALEX FASPRO can cause serious, life-threatening, or fatal infections. In patients who received DARZALEX FASPRO in a pooled safety population including patients with smoldering multiple myeloma and light chain (AL) amyloidosis (N=1639), serious infections, including opportunistic infections, occurred in 24% of patients, Grade 3 or 4 infections occurred in 22%, and fatal infections occurred in 2.5%. The most common type of serious infection reported was pneumonia (8.5%). Monitor patients for signs and symptoms of infection prior to and during treatment with DARZALEX FASPRO and treat appropriately. Administer prophylactic antimicrobials according to guidelines [see Dosage and Administration (2.6) ] . 5.4 Neutropenia Daratumumab may increase neutropenia induced by background therapy [see Adverse Reactions (6.1) ] . Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO until recovery of neutrophils. In lower body weight patients receiving DARZALEX FASPRO, higher rates of Grade 3–4 neutropenia were observed. 5.5 Thrombocytopenia Daratumumab may increase thrombocytopenia induced by background therapy [see Adverse Reactions (6.1) ] . Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Consider withholding DARZALEX FASPRO until recovery of platelets. 5.6 Embryo-Fetal Toxicity Based on the mechanism of action, DARZALEX FASPRO can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX FASPRO and for 3 months after the last dose [see Use in Specific Populations (8.1 , 8.3) ] . The combination of DARZALEX FASPRO with lenalidomide, thalidomide or pomalidomide is contraindicated in pregnant women, because lenalidomide, thalidomide or pomalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, thalidomide or pomalidomide prescribing information on use during pregnancy. 5.7 Interference with Serological Testing Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum [see References (15) ] . The determination of a patient's ABO and Rh blood type are not impacted [see Drug Interactions (7.1) ] . Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX FASPRO. Type and screen patients prior to starting DARZALEX FASPRO [see Dosage and Administration (2.1) ] . 5.8 Interference with Determination of Complete Response Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein [see Drug Interactions (7.1) ] . This interference can impact the determination of complete response and of disease progression in some DARZALEX FASPRO-treated patients with IgG kappa myeloma protein.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions table
<table width="75%" ID="table16"> <caption>Table 16: Select Hematology Laboratory Abnormalities Worsening from Baseline in Patients Who Received DARZALEX FASPRO with Lenalidomide and Dexamethasone (DARZALEX FASPRO-Rd) in PLEIADES</caption> <col width="33%" align="left" valign="bottom"/> <col width="34%" align="center" valign="bottom"/> <col width="33%" align="center" valign="bottom"/> <thead> <tr styleCode="Botrule"> <th rowspan="2" styleCode="Lrule Rrule">Laboratory Abnormality</th> <th colspan="2" align="center" styleCode="Rrule">DARZALEX FASPRO with Lenalidomide and Dexamethasone<footnote ID="K3055">Denominator is based on the safety population treated with DARZALEX FASPRO-Rd (N=65).</footnote> </th> </tr> <tr styleCode="Botrule"> <th align="center" styleCode="Rrule">All Grades (%)</th> <th styleCode="Rrule">Grades 3–4 (%)</th> </tr> </thead> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased leukocytes</td> <td styleCode="Rrule">94</td> <td styleCode="Rrule">34</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased lymphocytes</td> <td styleCode="Rrule">82</td> <td styleCode="Rrule">58</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased platelets</td> <td styleCode="Rrule">86</td> <td styleCode="Rrule">9</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased neutrophils</td> <td styleCode="Rrule">89</td> <td styleCode="Rrule">52</td> </tr> <tr> <td styleCode="Lrule Rrule">Decreased hemoglobin</td> <td styleCode="Rrule">45</td> <td styleCode="Rrule">8</td> </tr> </tbody> </table>
adverse reactions table
<table width="75%"> <caption>Table 17: Adverse Reactions Reported in ≥10% of Patients and With at Least a 5% Greater Frequency in the DARZALEX FASPRO-Pd Arm in APOLLO</caption> <col width="28%" align="left" valign="middle"/> <col width="18%" align="center" valign="middle"/> <col width="18%" align="center" valign="middle"/> <col width="18%" align="center" valign="middle"/> <col width="18%" align="center" valign="middle"/> <thead> <tr styleCode="Botrule"> <th rowspan="2" styleCode="Lrule Rrule" valign="bottom">Adverse Reaction</th> <th colspan="2" styleCode="Rrule" valign="bottom">DARZALEX FASPRO-Pd (N=149)</th> <th colspan="2" styleCode="Rrule" valign="bottom">Pd (N=150)</th> </tr> <tr> <th align="center" styleCode="Rrule">All Grades (%)</th> <th styleCode="Rrule">Grades ≥3 (%)</th> <th styleCode="Rrule">All Grades (%)</th> <th styleCode="Rrule">Grades ≥3 (%)</th> </tr> </thead> <tfoot> <tr> <td colspan="5" align="left"> Key: Pd=pomalidomide-dexamethasone</td> </tr> </tfoot> <tbody> <tr styleCode="Botrule"> <td colspan="3" styleCode="Lrule Rrule"> <content styleCode="bold">General disorders and administration site conditions</content> </td> <td styleCode="Rrule"/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Fatigue<footnote ID="K3246">Fatigue includes asthenia, and fatigue.</footnote> </td> <td styleCode="Rrule">46</td> <td styleCode="Rrule">13</td> <td styleCode="Rrule">39</td> <td styleCode="Rrule">5<footnote ID="tf2">Only Grade 3 adverse reactions occurred.</footnote> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Pyrexia</td> <td styleCode="Rrule">19</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">14</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Edema peripheral<footnote ID="K3285">Edema peripheral includes edema, edema peripheral and peripheral swelling.</footnote> </td> <td styleCode="Rrule">15</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">9</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td colspan="5" styleCode="Lrule Rrule"> <content styleCode="bold">Infections</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Pneumonia<footnote ID="K3312">Pneumonia includes atypical pneumonia, lower respiratory tract infection, pneumonia, pneumonia aspiration, pneumonia bacterial, and pneumonia respiratory syncytial viral.</footnote> </td> <td styleCode="Rrule">38</td> <td styleCode="Rrule">23<footnote ID="tf1">Grade 5 adverse reactions occurred, n=3 (2.0%) in the DARZALEX FASPRO-Pd arm and n=2 (1.3%) in the Pd arm.</footnote> </td> <td styleCode="Rrule">27</td> <td styleCode="Rrule">17<footnoteRef IDREF="tf1"/> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Upper respiratory infection<footnote ID="K3336">Upper respiratory tract infection includes nasopharyngitis, pharyngitis, respiratory syncytial virus infection, respiratory tract infection, respiratory tract infection viral, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection, and viral upper respiratory tract infection.</footnote> </td> <td styleCode="Rrule">36</td> <td styleCode="Rrule">1<footnoteRef IDREF="tf2"/> </td> <td styleCode="Rrule">22</td> <td styleCode="Rrule">2<footnoteRef IDREF="tf2"/> </td> </tr> <tr styleCode="Botrule"> <td colspan="3" styleCode="Lrule Rrule"> <content styleCode="bold">Gastrointestinal disorders</content> </td> <td styleCode="Rrule"/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Diarrhea</td> <td styleCode="Rrule">22</td> <td styleCode="Rrule">5<footnoteRef IDREF="tf2"/> </td> <td styleCode="Rrule">14</td> <td styleCode="Rrule">1<footnoteRef IDREF="tf2"/> </td> </tr> <tr styleCode="Botrule"> <td colspan="5" styleCode="Lrule Rrule"> <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content> </td> </tr> <tr> <td styleCode="Lrule Rrule"> Cough<footnote ID="K3399">Cough includes cough, and productive cough.</footnote> </td> <td styleCode="Rrule">13</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">8</td> <td styleCode="Rrule">0</td> </tr> </tbody> </table>
adverse reactions table
<table width="75%"> <caption>Table 18: Select Hematology Laboratory Abnormalities Worsening from Baseline in Patients Who Received DARZALEX FASPRO-Pd or Pd in APOLLO</caption> <col width="28%" align="left" valign="middle"/> <col width="18%" align="center" valign="middle"/> <col width="18%" align="center" valign="middle"/> <col width="18%" align="center" valign="middle"/> <col width="18%" align="center" valign="middle"/> <thead> <tr styleCode="Botrule"> <th rowspan="2" styleCode="Lrule Rrule" valign="bottom">Laboratory Abnormality</th> <th colspan="2" styleCode="Rrule">DARZALEX FASPRO-Pd<footnote ID="f1">Denominator is based on number of subjects with a baseline and post-baseline laboratory value for each laboratory test: N=148 for DARZALEX FASPRO-Pd and N=149 for Pd.</footnote> </th> <th colspan="2" styleCode="Rrule">Pd<footnoteRef IDREF="f1"/> </th> </tr> <tr> <th align="center" styleCode="Rrule">All Grades (%)</th> <th styleCode="Rrule">Grades 3–4 (%)</th> <th styleCode="Rrule">All Grades (%)</th> <th styleCode="Rrule">Grades 3–4 (%)</th> </tr> </thead> <tfoot> <tr> <td colspan="5" align="left"> Key: Pd=pomalidomide-dexamethasone</td> </tr> </tfoot> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased neutrophils</td> <td styleCode="Rrule">97</td> <td styleCode="Rrule">84</td> <td styleCode="Rrule">84</td> <td styleCode="Rrule">63</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased leukocytes</td> <td styleCode="Rrule">95</td> <td styleCode="Rrule">64</td> <td styleCode="Rrule">82</td> <td styleCode="Rrule">40</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased lymphocytes</td> <td styleCode="Rrule">93</td> <td styleCode="Rrule">59</td> <td styleCode="Rrule">79</td> <td styleCode="Rrule">33</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased platelets</td> <td styleCode="Rrule">75</td> <td styleCode="Rrule">19</td> <td styleCode="Rrule">60</td> <td styleCode="Rrule">19</td> </tr> <tr> <td styleCode="Lrule Rrule">Decreased hemoglobin</td> <td styleCode="Rrule">51</td> <td styleCode="Rrule">16</td> <td styleCode="Rrule">57</td> <td styleCode="Rrule">15</td> </tr> </tbody> </table>
adverse reactions table
<table width="75%"> <caption>Table 19: Adverse Reactions (≥10%) in Patients Who Received DARZALEX FASPRO with Carfilzomib and Dexamethasone (DARZALEX FASPRO-Kd) in PLEIADES</caption> <col width="50%" align="left" valign="top"/> <col width="30%" align="center" valign="top"/> <col width="20%" align="center" valign="top"/> <thead> <tr styleCode="Botrule"> <th rowspan="2" styleCode="Lrule Rrule" valign="bottom">Adverse Reaction</th> <th colspan="2" styleCode="Rrule">DARZALEX FASPRO-Kd (N=66)</th> </tr> <tr> <th align="center" styleCode="Rrule">All Grades (%)</th> <th styleCode="Rrule">Grade ≥3 (%)</th> </tr> </thead> <tbody> <tr styleCode="Botrule"> <td colspan="3" styleCode="Lrule Rrule"> <content styleCode="bold">Infections and infestations</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Upper respiratory tract infection<footnote ID="K3719">Upper respiratory tract infection includes nasopharyngitis, pharyngitis, respiratory tract infection, respiratory tract infection viral, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection, viral pharyngitis, and viral upper respiratory tract infection.</footnote> </td> <td styleCode="Rrule">52</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Bronchitis<footnote ID="K3732">Bronchitis includes bronchitis, and bronchitis viral.</footnote> </td> <td styleCode="Rrule">12</td> <td styleCode="Rrule">2<footnote ID="foot1a">Only Grade 3 adverse reactions occurred.</footnote> </td> </tr> <tr styleCode="Botrule"> <td colspan="3" styleCode="Lrule Rrule"> <content styleCode="bold">General disorders and administration site conditions</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Fatigue<footnote ID="K3756">Fatigue includes asthenia, and fatigue.</footnote> </td> <td styleCode="Rrule">39</td> <td styleCode="Rrule">2<footnoteRef IDREF="foot1a"/> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Pyrexia</td> <td styleCode="Rrule">21</td> <td styleCode="Rrule">2<footnoteRef IDREF="foot1a"/> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Edema peripheral<footnote ID="K3784">Edema peripheral includes generalized edema, edema peripheral, and peripheral swelling.</footnote> </td> <td styleCode="Rrule">20</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td colspan="3" styleCode="Lrule Rrule"> <content styleCode="bold">Psychiatric disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Insomnia</td> <td styleCode="Rrule">33</td> <td styleCode="Rrule">6<footnoteRef IDREF="foot1a"/> </td> </tr> <tr styleCode="Botrule"> <td colspan="3" styleCode="Lrule Rrule"> <content styleCode="bold">Vascular disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Hypertension<footnote ID="K3826">Hypertension includes blood pressure increased, and hypertension.</footnote> </td> <td styleCode="Rrule">32</td> <td styleCode="Rrule">21<footnoteRef IDREF="foot1a"/> </td> </tr> <tr styleCode="Botrule"> <td colspan="3" styleCode="Lrule Rrule"> <content styleCode="bold">Gastrointestinal disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Diarrhea</td> <td styleCode="Rrule">29</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Nausea</td> <td styleCode="Rrule">21</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Vomiting</td> <td styleCode="Rrule">15</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td colspan="3" styleCode="Lrule Rrule"> <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Cough<footnote ID="K3890">Cough includes cough, and productive cough.</footnote> </td> <td styleCode="Rrule">24</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Dyspnea<footnote ID="K3903">Dyspnea includes dyspnea, and dyspnea exertional.</footnote> </td> <td styleCode="Rrule">23</td> <td styleCode="Rrule">2<footnoteRef IDREF="foot1a"/> </td> </tr> <tr styleCode="Botrule"> <td colspan="3" styleCode="Lrule Rrule"> <content styleCode="bold">Nervous system disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Headache</td> <td styleCode="Rrule">23</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Peripheral sensory neuropathy</td> <td styleCode="Rrule">11</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td colspan="3" styleCode="Lrule Rrule"> <content styleCode="bold">Musculoskeletal and connective tissue disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Back pain</td> <td styleCode="Rrule">17</td> <td styleCode="Rrule">2<footnoteRef IDREF="foot1a"/> </td> </tr> <tr> <td styleCode="Lrule Rrule"> Musculoskeletal chest pain</td> <td styleCode="Rrule">11</td> <td styleCode="Rrule">0</td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.